XNASSTAA
Market cap1.13bUSD
Jan 10, Last price
23.00USD
1D
-0.52%
1Q
-27.24%
Jan 2017
111.98%
Name
STAAR Surgical Co
Chart & Performance
Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2021‑00 | 2020‑00 | 2018‑12 | 2017‑12 | 2016‑12 | 2016‑00 | |
Income | |||||||||
Revenues | 322,415 13.37% | 284,391 73.98% | |||||||
Cost of revenue | 292,926 | 240,589 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 29,489 | 43,802 | |||||||
NOPBT Margin | 9.15% | 15.40% | |||||||
Operating Taxes | 12,349 | 6,797 | |||||||
Tax Rate | 41.88% | 15.52% | |||||||
NOPAT | 17,140 | 37,005 | |||||||
Net income | 21,347 -46.18% | 39,665 570.81% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (2,096) | 1,000 | |||||||
BB yield | 0.14% | 0.00% | |||||||
Debt | |||||||||
Debt current | 8,734 | 3,693 | |||||||
Long-term debt | 67,301 | 58,385 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 5,158 | 2,155 | |||||||
Net debt | (156,394) | (163,463) | |||||||
Cash flow | |||||||||
Cash from operating activities | 14,594 | 35,715 | |||||||
CAPEX | (18,188) | (18,108) | |||||||
Cash from investing activities | 74,347 | (156,376) | |||||||
Cash from financing activities | 7,415 | 8,297 | |||||||
FCF | (49,510) | (46,429) | |||||||
Balance | |||||||||
Cash | 220,726 | 211,639 | |||||||
Long term investments | 11,703 | 13,902 | |||||||
Excess cash | 216,308 | 211,321 | |||||||
Stockholders' equity | (50,993) | (71,747) | |||||||
Invested Capital | 482,306 | 433,538 | |||||||
ROIC | 3.74% | 9.39% | |||||||
ROCE | 6.82% | 12.06% | |||||||
EV | |||||||||
Common stock shares outstanding | 49,427 | 49,380 | |||||||
Price | 31.21 -35.70% | 48.54 -38.73% | |||||||
Market cap | 1,542,617 -35.64% | 2,396,905 -36.90% | |||||||
EV | 1,386,223 | 2,233,442 | |||||||
EBITDA | 34,613 | 48,311 | |||||||
EV/EBITDA | 40.05 | 46.23 | |||||||
Interest | 2,448 | ||||||||
Interest/NOPBT | 5.59% |